These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18612550

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S, Jiménez-Yuste V, Santagostino E.
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
    Gringeri A.
    Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 29. [Immunosuppressive treatment of a spontaneous inhibitor hemophilia A using cyclophosphamide, vincristine and prednisone following prior Factor VIII stimulation].
    Dürig J, de Wit M, Fiedler W, Marx G, Hossfeld DK.
    Schweiz Med Wochenschr; 1996 Nov 23; 126(47):2026-31. PubMed ID: 8984611
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
    Kallas A, Kuuse S, Maimets T, Pooga M.
    Acta Haematol; 2008 Nov 23; 119(4):244-7. PubMed ID: 18594135
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Recombinant FVIIa in the treatment of bleeding in acquired hemophilia.
    Guerin V, Chossat I, Dutronc H, Dubreuil M, Valentin F.
    Am J Hematol; 2002 Aug 23; 70(4):333. PubMed ID: 12210820
    [No Abstract] [Full Text] [Related]

  • 36. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
    Ay Y, Ersin T, Yesim O, Hilkay KT, Dilek I, Gulcihan O, Ahmet K.
    Blood Coagul Fibrinolysis; 2016 Sep 23; 27(6):729-31. PubMed ID: 26484639
    [Abstract] [Full Text] [Related]

  • 37. Switching to low dose of plasma-derived factor VIII/vWF concentrates with Confact(®) -F as salvage immune tolerance induction in haemophilia A patients with inhibitors: five case reports from Japan.
    Nagao A, Oka T, Hanabusa H.
    Haemophilia; 2015 Sep 23; 21(5):e425-7. PubMed ID: 25996457
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
    Platokouki H, Pergantou H, Xafaki P, Komitopoulou A, Aronis S.
    Haemophilia; 2009 Mar 23; 15(2):617-9. PubMed ID: 19175417
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.